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Contrast-induced nephropathy is a common complication of iodinated contrast administration. Statins may reduce the risk of
contrast-induced nephropathy, but data remain inconclusive. We summarized the evidence based on statins for the prevention of
contrast-induced nephropathy with a network meta-analysis. Randomized trials focusing on statins were searched and pooled
with random-effect odds ratios. A total of 14 trials (6,160 patients) were included, focusing on atorvastatin (high/low dose),
rosuvastatin (high dose), simvastatin (high/low dose), and placebo or no statin therapy before contrast administration. The risk
of contrast-induced nephropathy was reduced by atorvastatin high dose and rosuvastatin high dose, with no difference between
these two agents. Results for atorvastatin low dose and simvastatin (high/low dose) in comparison to placebo were inconclusive.
Atorvastatin and rosuvastatin administered at high doses and before iodinated contrast administration have a consistent and
beneficial preventive effect on contrast-induced nephropathy and may actually halve its incidence.
1. Introduction
Iodinated contrast-induced nephropathy (CIN) is an impor-
tant cause of hospital-acquired acute renal injury [1].
Patients with acute coronary syndrome (ACS) and/or base-
line renal dysfunction, as well as those undergoing per-
cutaneous coronary intervention (PCI), are at particu-
larly high risk of CIN, which, when occurring, may be
followed by persistent worsening of renal function [2,
3]. To date, there have been many studies focusing on
the pathophysiology, epidemiology, risk prognostication,
and prevention of CIN. Yet, the pathophysiology of CIN
remains unclear but may be related to direct renal tubu-
lar toxicity, vasoconstriction, and high oxidative stress
[4, 5].
Statins are primarily used in cardiovascular medicine
for their lipid-lowering effects. However, they have recently
been shown to possess remarkable pleiotropic effects such
as improving endothelial function as well as decreasing
oxidative stress and inflammation [6]. In the context of
cardiovascular disease, nitric oxide-derived oxidant species
that promote atherogenesis are suppressed by statins [7].
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Therefore, statins are considered as promising candidate
agents for the prevention of CIN.
A number of studies have shown that statins may have
a protective effect on CIN, but there remains uncertainty
regarding time and way of administration of statins and it is
not clear whether a specific statin is better than the others.
Pairwise meta-analyses combine the results of homogeneous
studies conducted on the same topic, whereas network meta-
analyses evaluate simultaneously both direct and indirect
comparisons across trials sharing one or more common
comparators [21–23]. The purpose of our work was thus to
perform a systematic review including both pairwise and
network meta-analysis in order to evaluate more accurately
the effect of statins compared to placebo or standard therapies
for the prevention of CIN.
2. Methods
2.1. Design. The present review was conducted in keeping
with the current guidelines from the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA)
group and from the Cochrane Collaboration. All reviewing
activities were conducted by two independent reviewers (MP,
GBZ), with divergences solved after consensus.
2.2. Search. MEDLINE/PubMed was searched for suitable
studies according to Biondi-Zoccai et al., with the following
substring: [24] (statin∗ OR atorvastatin OR rosuvastatin OR
simvastatin OR lovastatin OR fluvastatin) AND (contrast
AND (nephropathy OR ((renal OR kidney) AND (injury
OR damage)))). In addition, the Cochrane Library, Google
Scholar, and Scopus were searched for additional studies. No
language restriction was enforced in order to minimize the
risk of publication bias, actually leading to the inclusion of
a study published only in Chinese [8]. Searches were last
updated on November 14, 2013, with the exception of the
MEDLINE/PubMed query, which was last performed on July
15, 2014.
2.3. Selection. Citations were initially screened at the
title/abstract level. If potentially pertinent, they were then
retrieved as full texts. Studies were included if randomized,
allocating one ormore groups to statin therapy and reporting
dichotomous outcomes relevant to the assessment of CIN.
Accordingly, studies were excluded if not randomized,
duplicated, focusing on nonstatin strategies, or lacking
suitable outcome details.
2.4. Abstraction and Validity. Study, patient, and procedural
features were systematically extracted, with a particular focus
on treatment strategy, type and volume of contrast, and CIN-
related outcomes. The primary endpoint was the occurrence,
at the longest in-hospital follow-up, of CIN, defined as a rela-
tive increase in serumcreatinine≥25%or an absolute increase
in serum creatinine ≥0.5mg/dL (44 𝜇mol/L), typically 48–72
hours after the index procedure. In addition, the following
endpoints were also collected at the longest in-hospital
follow-up: absolute increase in serum creatinine ≥0.5mg/dL
(44 𝜇mol/L); relative increase in serum creatinine ≥25%.
Conversely, the longest available clinical follow-up (thus
well beyond hospitalization, when available) was exploited
to abstract data on all-cause death and need for dialysis
or renal replacement therapy. Study validity was appraised
in keeping with ongoing recommendations distinguishing
several sources of bias typical of randomized trials [23].
2.5. Analysis. Categorical variables are described as n (%) and
continuous variables as median. Pairwise meta-analysis was
performed within a frequentist framework, computing odds
ratios (OR, 95% confidence intervals) by means of a Mantel-
Haenszel random-effect method [21]. Network meta-analysis
was performedwithin a Bayesian framework computing odds
ratios (95% credible intervals) and probability of being best
of any given treatment (Pbest) with a fixed-effect hierarchical
model, sampling posterior probabilities by means of Markov
chain Monte Carlo (MCMC) methods with Gibbs sampling
from 150,000 iterations obtained after a 50,000-iteration
training phase [22, 23]. Convergence was appraised graph-
ically according to Gelman and Rubin, and noninformative
priors were used throughout. A fixed-effect model was used
for network meta-analysis based on the star-shaped evidence
network, which is typically analyzed with such an approach,
and after having confirmed that model fit was not different
from a random-effect and a fixed-effect model computing
values for deviance information criterion (DIC). Pairwise
heterogeneity was appraised with chi-squared tests, whereas
network inconsistency was evaluated comparing the results
stemming from consistent and inconsistent models [21, 23].
Small study effects (e.g., publication bias) were explored
by visual inspection of funnel plots. Computations were
performed with RevMan and WinBUGS [23].
3. Results
From an initial set of 33,030 citations retrieved frommultiple
databases, a total of 30 articles were analyzed as full reports
according to our explicit selection criteria, finally yielding 14
studies eligible for inclusion in our review (Figure 1). These
trials included a total of 6,160 patients, according to the
following evidence network (Figures 2 and 3; Tables 1, 2, 3,
and 4): 4 studies (706 subjects) compared atorvastatin high
dose with atorvastatin low dose [8, 10, 14, 20], 5 studies (1246
subjects) compared atorvastatin high dose with placebo or
standard therapy without statins [13, 15–18], 1 study (192 sub-
jects) compared atorvastatin high dosewith rosuvastatin high
dose [11], 2 studies (3541 subjects) compared rosuvastatin
high dose with placebo or standard therapy without statins
[4, 12], 1 study (247 subjects) compared simvastatin high dose
with placebo or standard therapy without statins [9], and 1
study (228 subjects) compared simvastatin high dose with
simvastatin low dose [19].
Studies were clinically diverse, being conducted in Asia
and Europe, and included patients with diabetes mellitus
(median prevalence 23%) or mild to moderate chronic
kidney disease (median baseline serum creatinine 1.0mg/dL 1
(88 𝜇mol/L)). Several types of iodinated contrast media were
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33,030 initial citations: 
12 in CENTRAL
151 in MEDLINE/PubMed
1,867 in Scopus 
33,000 excluded because not 
pertinent 
31,000 in Google Scholar 
30 retrieved as full reports
16 excluded because not
fulfilling the selection criteria:
6 commentaries
2 lacking outcome data
4 observational studies
1 post hoc analysis
3 reviews
14 RCTs included in review
Figure 1: Review profile.
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Figure 2: Evidence network. Continuous lines represent head-to-head randomized comparisons (the thickness of the line corresponding to
the number of trials) with both direct and indirect effect estimates, whereas dashed lines represent only indirect effect estimates.The thickness
of the rectangles corresponds to the patients receiving a specific treatment.
used, including iobitridol, iodixanol, iohexol, iopamidol, and
iopromide (median volume 161mL). Study quality was ade-
quate inmost cases, but satisfactory details on randomization
procedures and thorough double blinding were present only
for 5 trials [9, 13, 16–18].
Pairwise meta-analysis for CIN was first conducted
to explore for overall clinical effects (online Figures
1–13 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/213239). These computations
showed that statins at high dose were associated with a
reduced risk of CIN (OR = 0.47 (95% confidence interval
0.37–0.60), P for effect <0.001, P for heterogeneity = 0.59, and
I-squared = 0%), of an absolute increase in serum creatinine
≥0.5mg/dL (OR = 0.57 (0.32–1.02), P for effect = 0.06, P for
heterogeneity = 0.26, and I-squared = 25%), and of a relative
increase in serum creatinine ≥25% (OR = 0.35 (0.17–0.69), P
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Figure 3: Forest plot summarizing risk estimates stemming from network meta-analysis comparing different statin regimens for the risk of
contrast-induced nephropathy. OR = odds ratio; CI = confidence interval; SE = standard error.
Table 1: Included studies.
First author Year Journal Patients Multicentersetting Location
Follow-up
(days) Selection criteria
Cao [8] 2012 Nan Fang Yi Ke DaXue Xue Bao 180 No China 3
ACS undergoing coronary
angiography or PCI without renal
failure
Han [4] 2013
Journal of the
American College of
Cardiology
2998 Yes China 30 Type 2 DM and stage 2-3 CKD
Jo [9] 2008 American HeartJournal 247 Yes Korea 180
CKD, statin naive, undergoing
coronary angiography
Jo [10] 2014
Journal of
Cardiovascular
Medicine
218 Yes Korea 180 STEMI undergoing emergency PCIirrespective of renal dysfunction
Kaya [11] 2013 Acta Cardiologica 192 No Turkey 2 STEMI undergoing emergency PCIwithout renal dysfunction
Leoncini [12] 2014
Journal of the
American College of
Cardiology
543 No Italy 180
NSTE-ACS, statin naive, selected for
early invasive strategy, without acute
or end-stage renal failure
Li [13] 2012 Cardiology 161 No China 30 STEMI undergoing emergency PCIwithout renal dysfunction
Li [14] 2014 Scientific WorldJournal 208 No China 1
Patients undergoing coronary
angiography or angioplasty
Özhan [15] 2010 Angiology 130 No Turkey 2
Patients undergoing coronary
angiography without renal
insufficiency (serum creatinine
<1.5mg/dL)
Patti [16] 2011 American Journal ofCardiology 241 Yes Italy 2
NSTE-ACS, statin naive, receiving
early PCI
Quintavalle [17] 2012 Circulation 410 Yes Italy 365 CKD, statin naive, scheduled forelective coronary angiography or PCI
Toso [18] 2010 American Journal ofCardiology 304 No Italy 30
CKD, statin naive, without end-stage
renal failure requiring dialysis
Xinwei [19] 2009 American Journal ofCardiology 228 No China 7 ACS undergoing PCI
Zhou [20] 2009 Zhonghua Xin XueGuan Bing Za Zhi 100 No China 3 Coronary angiography or PCI
ACS = acute coronary syndrome; CKD = chronic kidney disease; DM = diabetes mellitus; NSTE-ACS = non-ST-elevation ACS; PCI = percutaneous coronary
intervention; STEMI = ST-elevation myocardial infarction.
BioMed Research International 5
Table 2: Patient and procedural features.
First author Year Experimental therapy Controltherapy
Contrast
type
Median
contrast
volume
Age
(years)
Diabetes
mellitus
Baseline
serum
creatinine
(mg/dL)
Cao [8] 2012
Atorvastatin 40mg/day started 3
days before angioplasty followed
by atorvastatin 20mg/day
Atorvastatin
20mg/day NA 161 63 20% NA
Han [4] 2013
Rosuvastatin 10mg/day from 2
days before to 3 days after
contrast
No statin Iodixanol 115 61 100% 1.1
Jo [9] 2008
Simvastatin 40 + 40mg before
angiography followed by
simvastatin 40 + 40mg
afterwards
Placebo Iodixanol 182 65 26% 1.2
Jo [10] 2014
Atorvastatin 80mg before
angiography followed by
atorvastatin 80mg/day for 5 days
and then 10mg/day
Atorvastatin
10mg/day NA NA 60 26% 1.1
Kaya [11] 2013 Atorvastatin 80mg beforeangiography
Rosuvastatin
40mg before
angiography
Iopromide 153 63 20% 0.9
Leoncini [12] 2014 Rosuvastatin 40mg at admissionfollowed by 20mg/day No statin Iodixanol 261 66 21% 1.0
Li [13] 2012
Atorvastatin 80mg at admission
followed by atorvastatin 40mg
after angiography
Placebo Iopromide 102 66 28% 0.9
Li [14] 2014
Atorvastatin 40mg before
angiography, followed by
atorvastatin 40mg/day
Atorvastatin
20mg/day Iopamidol 186 61 24% 0.9
Özhan [15] 2010
Atorvastatin 80mg before
angiography, followed by
atorvastatin 80mg 48 hours after
contrast administration
No statin Iopamidol 95 55 16% 0.8
Patti [16] 2011
Atorvastatin 80mg 12 hrs before
angiography; further 40mg
preprocedure (2 hrs before),
followed by atorvastatin
40mg/day
Placebo Iobitridol 211 66 27% 1.0
Quintavalle [17] 2012
Atorvastatin 80mg (within
24 hrs before contrast exposure),
followed by atorvastatin
20mg/day
No statin Iodixanol 180 70 41% 1.3
Toso [18] 2010
Atorvastatin 80mg 48 hours
before and 48 hours after
contrast administration
Placebo Iodixanol 157 75 21% 1.2
Xinwei [19] 2009
Simvastatin 80mg from
admission to day before PCI,
followed by simvastatin
20mg/day
Simvastatin
20mg/day
Iodixanol
or iohexol 233 65 21% 0.8
Zhou [20] 2009
Atorvastatin 80mg/day before
the procedure, 10mg/day for 6
days after procedure
Atorvastatin
10mg/day for
7 days
Iopamidol 116 61 20% 1.1
NA = not available or applicable.
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Table 3: Internal validity of included studies.
First author Year Inadequate allocationsequence generation?
Inadequate allocation
concealment?
Inadequate
blinding?
Incomplete
outcome
data?
Selective outcome
reporting?
Risk of
other bias?
Cao [8] 2012 Unclear Unclear Unclear No Yes (lack of someindividual CIN data) No
Han [4] 2013 No No Yes (open label) No Yes (lack of someindividual CIN data) No
Jo [9] 2008 No No No No Yes (lack of someindividual CIN data) No
Jo [10] 2014 No Unclear Yes (open label) No Yes (lack of someindividual CIN data) No
Kaya [11] 2013 Unclear Unclear Yes (open label) No Yes (lack of someindividual CIN data) No
Leoncini [12] 2014 No Yes (open-label list) Yes (open label) No Yes (lack of someindividual CIN data) No
Li [13] 2012 No No No No Yes (lack of someindividual CIN data) No
Li [14] 2014 Unclear Unclear Yes (open label) No Yes (lack of someindividual CIN data) No
Özhan [15] 2010 Unclear Unclear Unclear No Yes (lack of someindividual CIN data) No
Patti [16] 2011 No No No No Yes (lack of someindividual CIN data) No
Quintavalle [17] 2012 No No No No Yes (lack of someindividual CIN data) No
Toso [18] 2010 No No No No Yes (lack of someindividual CIN data) No
Xinwei [19] 2009 No Yes (open-label study) Yes (open label) No Yes (lack of someindividual CIN data) No
Zhou [20] 2009 Unclear Unclear Unclear No Yes (lack of someindividual CIN data) No
CIN = contrast-induced nephropathy.
for effect = 0.003, P for heterogeneity = 0.57, and I-squared
= 0%). In addition, statins at high dose were associated with
trends toward reduced risks of in-hospital dialysis (OR =
0.27 (0.07–1.09), P for effect = 0.07, P for heterogeneity =
1.0, and I-squared = 0%) and death at a median follow-up of
3 months (OR = 0.80 (0.31–2.10), P for effect = 0.65, P for
heterogeneity = 0.61, and I-squared = 0%).
Subsequently, network meta-analysis was performed for
the risk of CIN, distinguishing atorvastatin high dose, ator-
vastatin low dose, rosuvastatin high dose, simvastatin high
dose, and simvastatin low dose. These computations showed
that atorvastatin high dose was the regimen which was most
likely to be beneficial (OR versus placebo= 0.49 (95% credible
interval 0.32–0.74), Pbest = 34%), followed by rosuvastatin
high dose (OR versus placebo = 0.49 (0.34–0.69), Pbest =
34%). Head-to-head comparison of atorvastatin high dose
versus rosuvastatin high dose suggested a very similar effect
(OR = 1.00 (0.61–1.64)). Data for simvastatin high dose were
apparently favorable, but inconclusive (OR versus placebo =
0.66 (0.14–3.04), Pbest = 32%), whereas data for atorvastatin
low dose and simvastatin low dose were clearly not in favor
of clinical use to prevent CIN (resp. OR versus placebo =
1.49 (0.69–3.45), Pbest < 0.1%, and OR versus placebo = 2.25
(0.37–14.61), Pbest = 0.2%). Additional network analyses for
the other CIN endpoints, dialysis, or death were not possible
for the paucity of reported events.
Consistency of pairwise and network analyses was sat-
isfactory, in light of the low I-squared estimates and the
similar results yielded by consistent, inconsistent, fixed-effect,
and random-effect Bayesianmodels. Even sensitivity analysis
excluding the largest study (Han et al.) [4] confirmed in direc-
tion and magnitude of effects the overall analysis (Table 5).
Finally, no clear evidence of small study effects was found at
funnel plot inspection (online Figures 3, 6, 9, 11, and 13).
4. Discussion
This review, the first in the literature exploiting the totality of
the evidence base with the novel mixed treatment compari-
son approach for comparative effectiveness analysis, confirms
that statins at high dose reduce the risk of CIN in patients
undergoing coronary angiography or revascularization with
current iodinated contrast media, with potentially beneficial
effects also on the risk of in-hospital dialysis. Moreover,
BioMed Research International 7
Table 4: Effect estimates for the risk of contrast-induced nephropathy. Results are reported as probability of being treatment (Pbest) and
odds ratios (OR) with 95% credible intervals of a given row item versus a corresponding column item. Thus, OR < 1 indicates lower risk in
the corresponding row item and OR > 1 indicates lower risk in the corresponding column item.
Treatment Atorvastatinhigh dose
Atorvastatin low
dose
Rosuvastatin
high dose
Simvastatin
high dose
Simvastatin low
dose
Placebo or no
statin
Atorvastatin
high dose Pbest = 34%
OR = 0.33
(0.16–0.63)
OR = 1.00
(0.61–1.64)
OR = 0.69
(0.12–4.35)
OR = 0.22
(0.03–1.35)
OR = 0.49
(0.32–0.74)
Atorvastatin low
dose
OR = 3.05
(1.59–6.21) Pbest < 0.1%
OR = 3.85
(1.27–14.29)
OR = 2.86
(0.41–24.39)
OR = 0.67
(0.09–5.01)
OR = 1.49
(0.69–3.45)
Rosuvastatin
high dose
OR = 1.00
(0.61–1.63)
OR = 0.26
(0.07–0.79) Pbest = 34%
OR = 0.76
(0.14–4.55)
OR = 0.73
(0.16–3.70)
OR = 0.49
(0.34–0.69)
Simvastatin
high dose
OR = 1.44
(0.23–8.11)
OR = 0.35
(0.04–2.42)
OR = 1.32
(0.22–7.13) Pbest = 32%
OR = 0.29
(0.10–0.72)
OR = 0.66
(0.14–3.04)
Simvastatin low
dose
OR = 4.61
(0.74–30.37)
OR = 1.50
(0.20–10.86)
OR = 1.37
(0.27–6.42)
OR = 3.40
(1.38–9.88) Pbest = 0.2%
OR = 2.25
(0.37–14.61)
Placebo or
no statin
OR = 2.05
(1.35–3.09)
OR = 0.67
(0.29–1.44)
OR = 2.04
(1.44–2.94)
OR = 1.51
(0.33–7.14)
OR = 0.44
(0.07–2.70) Pbest = 0
Table 5: Effect estimates for the risk of contrast-induced nephropathy excluding the study byHan et al. [4]. Results are reported as probability
of being best treatment (Pbest) and odds ratios (OR) with 95% credible intervals of a given row item versus a corresponding column item.
Thus, OR < 1 indicates lower risk in the corresponding row item and OR > 1 indicates lower risk in the corresponding column item.
Treatment Atorvastatinhigh dose
Atorvastatin low
dose
Rosuvastatin
high dose
Simvastatin
high dose
Simvastatin low
dose
Placebo or no
statin
Atorvastatin
high dose Pbest = 20%
OR = 0.32
(0.15–0.65)
OR = 1.22
(0.66–2.33)
OR = 0.65
(0.15–3.85)
OR = 0.19
(0.03–1.37)
OR = 0.47
(0.31–0.70)
Atorvastatin low
dose
OR = 3.12
(1.53–6.73) Pbest < 0.1%
OR = 3.85
(1.47–11.09)
OR = 2.08
(0.36–14.08)
OR = 0.60
(0.08–4.98)
OR = 1.45
(0.62–3.45)
Rosuvastatin
high dose
OR = 0.82
(0.43–1.51)
OR = 0.26
(0.10–0.68) Pbest = 34%
OR = 0.53
(0.12–3.23)
OR = 0.16
(0.02–1.22)
OR = 0.38
(0.22–0.65)
Simvastatin
high dose
OR = 1.54
(0.26–6.87)
OR = 0.48
(0.07–2.77)
OR = 1.90
(0.31–8.56) Pbest = 20%
OR = 0.29
(0.10–0.78)
OR = 0.72
(0.13–3.06)
Simvastatin low
dose
OR = 5.24
(0.73–32.12)
OR = 1.67
(0.20–12.66)
OR = 6.46
(0.82–41.28)
OR = 3.42
(1.28–10.03) Pbest = 0.2%
OR = 2.46
(0.35–14.17)
Placebo or
no statin
OR = 2.15
(1.42–3.28)
OR = 0.69
(0.29–1.61)
OR = 2.63
(1.54–4.55)
OR = 1.39
(0.33–7.69)
OR = 0.41
(0.07–2.86) Pbest = 0
network meta-analysis suggests that atorvastatin and rosu-
vastatin at high dose represent the first choice regimens in
order to achieve a consistent and beneficial preventive effect
on CIN and may actually halve its incidence.
Invasive angiography exploiting iodinated contrastmedia
may be complicated in several cases by CIN, with a negative
impact on prognosis, hospital stay, and costs [25]. Accord-
ingly, means to prevent it may yield important and clinically
relevant benefits. Yet, its pathophysiology remains unclear.
It may be due to direct toxicity on the renal tubular epithe-
lium, oxidative stress, ischemic injury, and renal tubular
obstruction, as any change in nitric oxide, prostaglandins,
endothelin, and adenosine in the vasoregulation pathway
could contribute to worsen medullary ischemia [26]. Many
preventive strategies and treatments have been proposed for
CIN, although only few are with a demonstrated clinical
efficacy [25, 27, 28].
In addition to their impact on cholesterol, statins are
known to have multiple nonlipid lowering (i.e., pleiotropic)
effects, which include several mechanisms involving inflam-
mation responses, endothelial function, oxidative stress, and
apoptotic pathways [17]. Preventing contrast-induced renal
cell apoptosis seems to play an important role in statins effects
on CIN. Because inflammation is unquestionably involved in
the pathogenesis of kidney injury, its modulation could be
part of the mechanism expounding the reduced incidence
of CIN after treatment with statins. The antioxidant effect of
statins in addition to other antioxidant compounds (sodium
bicarbonate solution and N-acetylcysteine) seems to reduce
the occurrence of CIN just through scavenging reactive
oxygen species (ROS) [14]. Khanal et al. firstly reported, in
a retrospective study that evaluated a large cohort of patients
who underwent PCI, that patients on chronic statin therapy
before the procedure had a significantly lower incidence of
CIN [29]. Thereafter, several prospective nonrandomized or
randomized placebo controlled trials suggested that a short-
term regimen of high-dose statins before and after contrast
exposure, in addition to standard measures for preventing
8 BioMed Research International
kidney deterioration, might decrease the incidence of CIN.
Nevertheless, the type and the dose threshold of statins to
reduce the risk of CIN remained uncertain.
Our meta-analysis represents the first work to exploit
network meta-analytic methods to compare different statins
in their CIN preventive effects. It shows that atorvastatin and
rosuvastatin, when administered at high dose, represent the
most effective preventive strategy. Accordingly, the present
work provides important findings in support of the favorable
risk-benefit balance of statins to prevent CIN, as offering
patients a short-term yet high-dose statin regimen before
administration of iodinated contrast appears as a remarkably
safe, simple, and effective intervention.
Focusing on current pharmacopeia, all statins are admin-
istered in active form except lovastatin and simvastatin which
are given as a prodrug and converted in vivo into the liver.
More of 90% of statins are bound to plasma proteins, but
rosuvastatin has a lower rate of link (88%). This is due to
the hydrophilicity features of this molecule limiting the need
for its transport in the blood through albumin. Hydrophilic
statins encompass acute pleiotropic effects. Moreover, they
do not undergo cytochrome P-450 3A4 metabolism in the
liver. These features may explain, at least in part, potential
differences between statins in CIN prevention. In addition,
as CIN is a paradigm of mutual hypoxic and toxic renal
parenchymal injurymediated, to large extent, by an increased
production of mediators of inflammation and ROS and
clinical as well as experimental findings clearly illustrate that
hypoxia and enhanced ROS formation within the kidney
following contrast media administration play a critical role in
the development of CIN [30], we speculate that atorvastatin
and rosuvastatin may be more effective than other statins
probably due to their higher anti-inflammation and antiox-
idant features.
This work has several limitations, including those typical
of systematic reviews, pairwise meta-analyses and mixed
treatment comparisons [21, 23]. More poignantly to the
current findings, we exploited an evidence network with
a prevalent star shape. In addition, we relied on surrogate
outcomes for renal function, which have been called into
question for being overly sensitive and subject to substantial
between- and within-individual variability. In particular,
relative increases in serum creatinine ≥25% may occur in
many patients irrespectively of the amount of administered
contrast. In addition, no study focused on noncoronary
contrast media administration, and thus the implications of
our results for other imaging procedures (e.g., computed
tomography) are open to individual interpretation. Finally,
due to the lack of patient-level data, key moderators on
the risk of CIN, such as means of contrast administration
(intravenous versus intra-arterial), volume of contrast, type
of contrast [25], and baseline use of statins, could not be
appraised quantitatively.
5. Conclusion
Atorvastatin and rosuvastatin, when administered at high
doses and before iodinated contrast administration, have a
consistent and beneficial preventive effect on CIN and may
actually halve its incidence.
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